and 77.2% after switch in type 1 patients, and 80.4% and 76.8%, respectively in type 2 patients, p 0.05)./p pConclusion/p pIn routine clinical practice, switching from NPH to glargine provides the opportunity for improving glycaemic control in diabetes patients inadequately controlled by NPH./...
The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080-3086. doi:10.2337/diacare.26.11.3080PubMedGoogle ScholarCrossref 7. Lipska KJ, Parker MM, Moffet HH, Huang ES, Karter AJ. ...
(2009) Switching from NPH to insulin glargine positively impacts on glycemic control and psy- chological well-being in suboptimally controlled type 2 diabetes patients. An observational study. Diabetes, 58, A537Hajos, T., et al. (2009) Switching from NPH to insulin gla...
PDB2 IMPROVED GLYCAEMIC CONTROL BY SWITCHING FROM INSULIN NPHTO INSULIN GLARGINE: A RETROSPECTIVE OBSERVATIONAL STUDYdoi:10.1016/S1098-3015(10)66649-1JP Gordon and P Sharplin and J Peters and AP Tetlow and AJ Longman and P McEwanValue in Health...
Curington R, Espel M, Heaton PC, Luder H, Brown B. Clinical outcomes of switching from insulin glargine to NPH insulin in indigent patients at a charitable pharmacy: the Charitable Insulin NPH: Care for the Indigent (CINCI) study. J Am Pharm Assoc. 2017;57(3S):S229eS235....
Glycemic control improved significantly from baseline week 24 in the pre-study NPH insulin and insulin-glargine groups (P < 0.001), while it appeared to improve in the pre-study basal-bolus group. Quality of life was positively impacted after 24 weeks in all 3 groups. Conclusion: The switch...
Aims:The aim of this analysis was to assess the cost-effectiveness of switching from biphasic human insulin 30 (BHI), insulin glargine (IGlar), or neutral protamine Hagedorn (NPH) insulin (all卤oral glucose-lowering drugs [OGLDs]) to biphasic insulin aspart 30 (BIAsp 30) in people with ...
to IDet analogue bolus (n 349); Group (2) NPH HI bolus switching to IDet HI bolus (n 500); Group (3) NPH analogue bolus switching to IDet analogue bolus (n 1144); Group (4) Glargine analogue bolus switching to IDet ...
Introduction: Using pooled data from the REALI European database, we evaluated the impact of previous basal insulin (BI) type on real-life effectiveness and safety of switching to insulin glargine 300 U/ml (Gla-300) in people with suboptimally controlled type 2 diabetes. Methods: Patient-...
McEwan P, Mehin N, Tetlow AP, Sharplin P.The relative cost effectiveness of switching to insulin glargine versus NPH insulin in insulin naive and non insulin naive Type 2 diabetes patients using UK real life data. Value in Health 10: A223, No. 6, Nov-Dec 2007...